HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively evaluate the prognostic/predictive significance of the above parameters in early, high-risk br...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: George Fountzilas, Christos Valavanis, Vassiliki Kotoula, Anastasia G Eleftheraki, Konstantine T. Kalogeras, Olympia Tzaida, Anna Batistatou, Ralf Kronenwett, Ralph M. Wirtz, Mattheos Bobos, Eleni Timotheadou, Nikolaos Soupos, George Pentheroudakis, Helen Gogas, Dimitrios Vlachodimitropoulos, Genovefa Polychronidou, Gerasimos Aravantinos, Angelos Koutras, Christos Christodoulou, Dimitrios Pectasides, P. Arapantoni
Médium: Artigo
Jazyk:angličtina
Vydáno: 2012
On-line přístup:https://doi.org/10.1186/1479-5876-10-10
https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/1479-5876-10-10
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1186/1479-5876-10-10
https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/1479-5876-10-10

Podobné jednotky